20.500.12556/DKUM-81986 Patch testing with the European baseline series and 10 added allergens single centre study of 748 patients Background: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥ 0.5% prevalence rate. Objectives: We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co-reactivity of additional allergens. Methods: Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 hours. Readings were done on day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. Retrospective analysis was done. Results: Eight allergens not listed in the EBS had ≥ 0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea, propylene glycol, Compositae mix II, and dexamethasone-21-phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings. Conclusion: We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea, and Compositae mix II need to be added to the EBS. clinical epidemiology baseline series contact sensitization patch tests simultaneous reactivity klinična epidemiologija osnovna serija kontaktna senzibilizacija kožni testi z obliži sočasna reaktivnost true false true Blackwell Angleški jezik Slovenski jezik Znanstveno delo 2022-06-26 06:54:29 2023-07-13 08:58:05 2024-07-16 14:53:02 0000-00-00 00:00:00 2022 0 0 Str. 439-446 Št. 5 Letn. 87 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 2022-04-27 2022-06-21 2022-06-23 616-097 112721411 10.1111/cod.14178 1600-0536 RAZ_Bizjak_Mojca_2022.pdf RAZ_Bizjak_Mojca_2022.pdf 1 1F4F45BEA26B68B7F7F94B299890234C a5508f3e68fe12d88469013376e9637ce2f5e109a2161d3261566426f51d87c3 68263baf-214b-11ee-a0bb-00155d000105 https://dk.um.si/Dokument.php?lang=slv&id=168741 https://doi.org/10.1111/cod.14178 0 10437278-f50c-11ec-b243-00155d000105 https://dk.um.si/Dokument.php?lang=slv&id=158927 Medicinska fakulteta 0 0 0